Community peer support for screening methamphetamine-related heart failure
Official title: Rural Community Peer Partnerships for Improving Methamphetamine-Associated Heart Failure Screening and Engagement
Run by Oregon Health and Science University · NCT06461962 · Data updated 2026-11-12
This study is testing a new way to help people in rural areas who have heart failure from methamphetamine use by connecting them with peer support and cardiology care.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | Oregon Health and Science University Academic / other |
| Locations | 1 site (Portland, Oregon) |
| Status | Recruiting |
| Started | August 19, 2024 |
| Main results expected | June 30, 2029 |
| Study ends | June 30, 2029 |
| Registry record updated | October 22, 2026 |
| Trial ID | NCT06461962 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older who regularly use methamphetamine and show signs of potential heart failure but have not been diagnosed with heart failure.
✕Probably not a fit
Patients who have engaged in medical care for heart failure in the past six months or are currently taking heart failure medications may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to implement and evaluate a community peer-facilitated approach to screen for methamphetamine-associated heart failure (MAHF) and connect individuals to cardiology care in rural areas. Given the rising rates of methamphetamine use and associated heart failure in these communities, the study addresses significant barriers to accessing medical care, including stigma and distrust of healthcare providers. The intervention includes treatment as usual and telehealth cardiology services to improve engagement and outcomes for affected individuals. The feasibility and preliminary effectiveness of this approach will be assessed to inform future interventions.
Why it matters
Potential benefit: If successful, this study could enhance access to essential cardiac care for individuals using methamphetamine, potentially improving their health outcomes.
How similar studies have gone: While similar interventions have been successful in urban settings, this approach is novel in rural communities and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient-defined regular use of methamphetamine in the last year * Any methamphetamine use in the past 30 days * Age 18 years or older * No client-reported diagnosis of heart failure * Able to communicate in English * Screen positive for potential methamphetamine-associated heart failure (MAHF) defined as B type natriuretic peptide (BNP) ≥50 pg/ml, or QRS width ≥120ms, or presence of any clinical heart failure symptoms Exclusion Criteria: * Self-reported engagement in medical care for heart failure in past 6 months. * Actively taking medications for heart failure.
Where it's running
-
Oregon Health & Science University
Portland, Oregon, United States Recruiting
Study contacts
- Principal investigator: Brian Chan, MD, MPH — Oregon Health and Science University
- Study coordinator: Brian Chan, MD, MPH
- Email: chanbri@ohsu.edu
- Phone: 503-494-2010
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Using Apple Watch data to predict heart failure outcomes
This study is testing if data from Apple Watches can help predict heart failure problems and the chances of needing to go back to the hospital for patients with heart failure.
-
Comparing Aortix Device to Diuretics for Acute Heart Failure
This study is testing whether the Aortix device can help people with acute heart failure who aren't responding to diuretics feel better compared to standard treatment.
-
Myocardial Energetics Across Cardiovascular Disease Spectrum Using 31P-MRS
Researchers are testing whether phosphorus-31 magnetic resonance spectroscopy (31P-MRS) can map heart energy metabolism across healthy people and patients with various heart conditions.
-
Tailored digital support to cut sedentary time in long-term cardiac rehab
In adults in a long-term cardiac rehabilitation program, this study tests whether a personalized behavioural program with digital tools can reduce daily sitting time.
-
NT-proBNP–guided heart failure screening for people 65+ in rural China
This study tests whether using NT-proBNP blood tests to guide heart failure screening in adults 65 and older in rural China can find unrecognized heart problems more effectively than symptom-based screening.
-
Voice-based detection of heart failure deterioration using Noah Labs Vox
This study tests whether a voice-analysis app can flag worsening heart failure in adults by comparing its alerts to standard weight-based monitoring.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.